ArticleMolecules (Basel, Switzerland)2026
Bumetanide/Synthetic Saponite Composites: Performant Systems for Enhanced Drug Dissolution Rate.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bumetanide is an efficient diuretic drug with poor water solubility and dissolution rate. In this study, bumetanide/synthetic saponite systems with enhanced solubility and dissolution rate are developed. Different synthetic strategies (hydrothermal and sol-gel) and aluminum contents are explored to prepare saponites with adjustable stacking. Bumetanide loading is achieved by a solution method. The synthetic route is feasible and scalable. Crystalline and non-crystalline bumetanide co-exist in the hybrids, and the non-crystalline fraction prevails in stacked saponite-based composites. Electrostatic interaction occurs between the negatively charged smectite layers and the protonated anilinic group, and the molecules accommodate within the interlayer spacing of stacked saponites. Compared with bumetanide, all the composites improve water solubility, wettability, and dissolution rate in simulated gastric conditions (pH 1.2 and 4.5) and deionized water. The samples with drug intercalation and a reduced fraction of crystalline bumetanide are the best-performing. The drug release is favoured at pH ≥ 4.5, as electrostatic repulsion occurs between the saponite layers and the carboxylate group of bumetanide. The complete release of the bumetanide dose, not achieved in sufficiently short times for all the fluids considered, is reached in the formulation with appropriate excipients. Bumetanide/saponite composites revealed performant and tuneable systems for bumetanide solubility and dissolution rate enhancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.